Clinical Trial Update: Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of axitinib monotherapy in chemorefractory third-line metastatic colorectal cancer completed, with results posted after dynamic contrast-enhance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Imperial College London | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-04-16